10X Genomics Hits Day High with 8.39% Surge Amid Market Volatility

10X Genomics, Inc., a small-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable uptick in its stock performance today, gaining 8.39% as of March 17, 2026. The stock reached an intraday high of USD 18.15, reflecting a significant movement in the market. Over the past year, 10X Genomics has outperformed the S&P 500, delivering a remarkable return of 68.12% compared to the broader index's 18.34%. However, the stock has faced challenges in the short term, with a 1-week decline of 11.58% and a 1-month decrease of 2.85%. Despite these fluctuations, the year-to-date performance remains positive at 10.91%. The company boasts a strong institutional ownership at 100%, indicating a robust backing from investors who typically have the resources to analyze company fundamentals effectively. Financial metrics reveal that 10X Genomics has achieved its highest operating cash flow at USD 136.05 million, although it continues to navigate a challenging landscape with a negative return on equity of -10.80%. Overall, the stock's performance today highlights its dynamic position within the market.